Researchers at UC Irvine have developed a novel immunofluorescent imaging strategy to identify cell subsets of interest, in particular cancer stem cells, endothelial progenitor cells, and other primary adherent cells from tumor biopsies.
Complex tissues such as tumors contain various cellular subsets each of which contribute in different ways to the biological behavior and phenotype. Enumerating the propertion of these cellular subsets is highly likely to impact the ability to rationally design individualized therapeutic strategies to limit toxicity and optimize clinical benefit.
Researchers at UC Irvine have invented a method to identify cells from a large mixed population by leveraging the unique patterns of cell marker molecules for each cellular subset. By labelling fluorescently-conguated monoclonal antibodies (mAbs) specific to cell markers, researchers are able to interrogate the presence or absence and relative level of expression of each of the cell markers using laser scanning confocal microscopy. This multicolor immunofluorescent imaging strategy enables the user to unquely identify and enumerate primary human cells with different phenotypes from complex tumor samples, amongst other tissues.
Suggested uses for this technology include identification, enumeration, and isolation of cell subsets from a complex tissue. This can be further used to design personalized treatments based off tissue makeup.
-Permits simultaneous enumeration of various cellular elements present within a complex adherent cell sample
-Provides the opportunity to assess selected molecular profiles of individual cells from these various cellular compartments
-Can be available to patients at the time of diagnosis vs. after tumor resection
-Overcomes limitations to existing technologies, and
-Is designed for high throughput analysis.
|United States Of America||Published Application||20140147861||05/29/2014||2012-665|